FY2029 Earnings Estimate for PLRX Issued By HC Wainwright

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Pliant Therapeutics in a research note issued on Monday, February 10th. HC Wainwright analyst E. Arce expects that the company will post earnings of $1.75 per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

A number of other research firms have also commented on PLRX. Wells Fargo & Company lowered shares of Pliant Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $41.00 to $4.00 in a research report on Monday. Oppenheimer reissued a “market perform” rating on shares of Pliant Therapeutics in a report on Monday. Royal Bank of Canada cut shares of Pliant Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $45.00 to $4.00 in a report on Monday. Needham & Company LLC lowered their price objective on Pliant Therapeutics from $38.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Citigroup cut Pliant Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $40.00 to $4.00 in a research report on Monday. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $17.75.

Pliant Therapeutics Stock Down 15.0 %

PLRX stock opened at $2.61 on Wednesday. The stock has a 50-day simple moving average of $12.18 and a two-hundred day simple moving average of $12.79. Pliant Therapeutics has a twelve month low of $2.60 and a twelve month high of $18.00. The firm has a market capitalization of $158.82 million, a PE ratio of -0.78 and a beta of 1.03. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09.

Insider Activity at Pliant Therapeutics

In other news, General Counsel Mike Ouimette sold 13,270 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $148,624.00. Following the completion of the sale, the general counsel now directly owns 80,774 shares in the company, valued at approximately $904,668.80. The trade was a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Hans Hull sold 15,936 shares of the company’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the sale, the insider now directly owns 211,558 shares of the company’s stock, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,855 shares of company stock valued at $1,026,628 over the last 90 days. 6.40% of the stock is owned by insiders.

Institutional Trading of Pliant Therapeutics

Several hedge funds have recently added to or reduced their stakes in PLRX. R Squared Ltd bought a new position in shares of Pliant Therapeutics during the fourth quarter valued at about $33,000. KLP Kapitalforvaltning AS purchased a new stake in Pliant Therapeutics during the 4th quarter valued at about $108,000. Atria Investments Inc bought a new position in Pliant Therapeutics during the 3rd quarter worth approximately $112,000. China Universal Asset Management Co. Ltd. increased its stake in Pliant Therapeutics by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock worth $131,000 after purchasing an additional 4,607 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Pliant Therapeutics in the third quarter valued at approximately $145,000. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.